As of September 2024, Uzbekistan’s pharmaceutical market reached 20.3 trillion soums, reflecting an annual growth rate of 13%, according to data from the pharmaceutical company STADA.
Notably, 98% of drug sales in the country occur in retail, with prescription drugs making up 70% of those sales.
As reported by Proxima Research, in September of the previous year, the leading companies in the Uzbek pharmaceutical market included KRKA, with a 3.5% market share, Stada, with 3.1%, and Yuria-Pharm, with 3%. The residents of Tashkent spent the most on medicines, accounting for 31.4% of all drug sales in the country.
The capital region followed with 9.1% of purchases, and the Samarkand region accounted for 8.9%. Conversely, the Syrdarya region reported the lowest spending on medicines, representing just 1.4% of total sales.
Kursiv Uzbekistan also reports that duties on imported antibiotics will be implemented in April of this year.
